Phase II trial of 4′‐deoxydoxorubicin (DxDx) in non‐small cell lung cancer: A cancer and leukemia group B trial
作者:
Q. Scott Ringenberg,
Michael C. Perry,
Kathleen J. Propert,
Caron Modeas,
Vera Hirsh,
Raymond B. Weiss,
Frederick Richards,
Stephen Graziano,
Mark Green,
期刊:
Medical and Pediatric Oncology
(WILEY Available online 1988)
卷期:
Volume 16,
issue 1
页码: 27-29
ISSN:0098-1532
年代: 1988
DOI:10.1002/mpo.2950160107
出版商: Wiley Subscription Services, Inc., A Wiley Company
关键词: esorubicin;anthracycline analogue;tumor;antitumor activity;metastatic disease
数据来源: WILEY
摘要:
AbstractEighty‐seven patients with histologically or cytologically proven non‐small‐cell carcinoma of the lung were treated with 4′‐deoxydoxo‐rubicin (DxDx) 30 mg/m2every 3 weeks. Three responses (4%), all partial, were observed. All responses occurred in patients with large‐cell anaplastic lung cancer and none in squamous or adenocarcinoma histologies (P<0.01). The durations of partial response for these three responders were 70, 198+ and 209+ days. The side effects noted were predominantly neutropenia, anemia, and weight loss. In three patients, declines in cardiac ejection fraction of 7%, 12%, and 23% occurred after cumulative drug doses of 150 mg/m2, 150 mg/m2, and 233 mg/m2, respectively. 4′‐Deoxydoxorubicin had little activity in non‐small‐cell lung cancer at the do
点击下载:
PDF
(225KB)
返 回